on BIOSYNEX (EPA:ALBIO)
BIOSYNEX postpones the publication of its 2025 annual accounts
The BIOSYNEX Group, a specialist in healthcare diagnostics, has announced the postponement of the release of its annual accounts and 2025 financial report. This delay is due to additional work required by ongoing safeguard proceedings. Originally scheduled for April 22, 2026, the publication will now take place on April 30, 2026, after the market closes. On the same day, the revenue figures for the first quarter of 2026 will be released.
Based in Illkirch-Graffenstaden, BIOSYNEX is a major player in rapid testing, biotherapy monitoring, and molecular biology. The group is listed on Euronext Growth Paris and generated revenue of €95.1 million in 2025.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news